Isis and Collaborators Present New Research at the ATVB Annual ...( WASHINGTON and CARLSBAD Calif. May 1 ...),Health

WASHINGTON and CARLSBAD, Calif., May 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Isis and collaborators presented data on numerous advanced programs from Isis' cardiovascular franchise. The data were presented during the Arteriosclerosis, Thrombosis and Vascular Biology's (ATVB) Annual Conference. The presentations included data from a post-hoc analysis of a recently completed clinical study of mipomersen in which treatment with mipomersen resulted in a decrease in apoC-III. In addition, Isis presented preclinical data from two late-stage research programs, one on a direct antisense inhibitor of apoC-III, which may provide a promising new drug to lower triglycerides, and a second on an antisense inhibitor to Factor XI, which has the potential to create a drug to decrease clotting without increasing bleeding. Both of these programs are expected to produce near-term clinical development candidates that have the potential to provide unique treatments for cardiovascular disease. Isis and collaborators also presented data on antisense inhibitors against 11 beta-HSD1 and apoF, potential new cardiovascular targets. The research presented at this year's ATVB in Washington D.C. showcases Isis' prolific antisense drug discovery capabilities and supports the continued expansion of Isis' cardiovascular franchise.

At ATVB, Isis collaborator, Dr. Frank Sacks, Professor of Cardiovascular Disease Prevention at the Harvard School of Public Health, presented a post-hoc analysis on a Phase 2 study in patients with high cholesterol who were treated with mipomersen as a single agent. Dr. Sacks' analysis showed that treatment with mipomersen reduced circulating apoC-III. ApoC-III is an apolipoprotein that transports triglycerides in the blood. Patients with cardiovascular disease frequently have elevated le
'/>"/>